Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 53 Pages
|Breo Ellipta(氣喘):市場預測與分析 Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023|
|出版日期: 2014年08月31日||內容資訊: 英文 53 Pages||
Breo Ellipta(歐洲是以Relvar Ellipta之名上市)，是糖酸Fluticasone和vilanterol trifenatate的FDC(固定劑量複方藥物)，用於同時需要ICS(吸入用類固醇藥)和LABA(長效型β2刺激藥)的氣喘患者的維持療法上。使用上利用Ellipta這個新的DPI(乾粉吸入器)。配合成分之一的糖酸Fluticasone是具有潛在消炎效果的合成三氟化皮質類固醇，可減為一日只要給藥一次，這關係到患者依從性及治療成績的改善。糖酸Fluticasone更朝向比GSK更獨立型的ICS治療藥方向開發。
本報告提供氣喘治療藥之一──Breo Ellipta的全球市場相關分析，提供氣喘概要和治療方法，競爭的企業、藥品概要，市場競爭概況，Breo Ellipta的商品資訊(特色·功效·安全性等)，全球主要國家的市場銷售額預測(今後10年份)等調查，並將結果概述為以下內容。
GlobalData has released its new PharmaPoint Drug Evaluation report, "Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Breo Ellipta (or Relvar Ellipta in Europe) is an FDC of fluticasone furoate and vilanterol trifenatate for the maintenance treatment of asthma in patients who need both an ICS and a LABA. Breo is dosed via a new DPI device, Ellipta. Breo's pharmacodynamics allow for once-daily administration, and it is going to be the first FDC that allows for once-daily administration for the maintenance treatment of asthma. This is due to its ICS component, fluticasone furoate, which is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity that can be dosed once a day, thus improving patient compliance and treatment outcomes. Fluticasone furoate is also being developed by GSK as a stand-alone ICS therapy.